Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow. It occurs when the bone marrow, which is responsible for producing blood cells, starts making too many abnormal white blood cells called myeloblasts. These abnormal cells crowd out healthy blood cells, leading to a shortage of red blood cells (which carry oxygen), platelets (which help with blood clotting), and normal white blood cells (which fight infections). AML can make a person feel weak, tired, and more susceptible to infections. The treatment for Acute Myeloid Leukemia (AML) typically involves a combination of therapies, like Chemotherapy, Stem Cell Transplant, Targeted Therapy, Care and Clinical Trials. The Global Acute Myeloid Leukemia (AML) Treatment Market report examines the worldwide market of AML treatment. It includes a detailed analysis and prediction of commercially significant products like targeted therapies, anthracycline drugs, and chemotherapies.
The Acute Myeloid Leukemia (AML) treatment market is expected to grow from $3.8B in 2023 to $6.1B by 2028, at a compound annual growth rate (CAGR) of 10.0% from 2023 to 2028. Growth in this market is fuelled by a worldwide increase in elder populations and an increased prevalence of AML., a type of blood cancer affecting many individuals, worldwide. This market has seen significant growth in recent years due to more effective treatment options, which introduce targeted therapies, immunotherapies and combination therapies that specifically target the genetic mutations and abnormalities in AML cells. These advancements improve treatment outcomes and survival rates for AML patients, driving the demand for these therapies in the market. Elder population, exposure to environmental toxins, and genetic susceptibility factors, led to a notable rise in AML cases, driving the demand for AML treatment options. In 2020, AML treatment was significantly impacted by the COVID-19 pandemic, which led to the shutdown of cancer hospitals and chemotherapy procedures.
AbbVie is a multinational pharmaceutical company headquartered in North Chicago, Illinois, USA. AbbVie is known for its focus on research and development in the fields of immunology, oncology, neuroscience, virology, and general medicine.
Bayer is a life sciences company with core competencies in the areas of healthcare and agriculture. Bayer’s pharmaceutical division focuses on prescription products, especially for cardiology, women’s health, and specialty therapeutics in oncology, hematology, and ophthalmology. Cell and gene therapy is a focus area for the company, as they have established an independent strategic unit for this.
Bristol-Myers Squibb (BMS) is a specialized biopharmaceutical corporation involved in various aspects of the medical industry. The company primarily concentrates on cancer, cardiovascular diseases, immunology, and fibrosis-related therapeutic projects. The company predominately works in oncology, hematology, immunology, cardiovascular and neuroscience.